KURA News and Press, Kura Oncology Inc. From 10/30/23

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, ...

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the clo...

2023-10-25 16:02:55 ET More on Syndax Pharmaceuticals Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023 Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript Syndax i...

– Phase 1 dose-escalation study to evaluate KO-2806 as a monotherapy and in combination with targeted therapies in KRAS G12C -mutant NSCLC and ccRCC – SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company ...

– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR – – Data validate activity of farnesyltransferase inhibitors and support rapid advancement of KO-2806 into combinations with targeted therapies in large solid tumor indication...

– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRAS G12C inhibitors and KRAS G12 D inhibitors – SAN DIEGO, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage...

– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRAS G12C inhibitors – – Company to include KRAS G12C -mutant NSCLC in combination portion of Phase 1 clinical trial of KO-2806 (FIT-001) – SAN DIEGO, Sept...

2023-09-25 04:40:22 ET Summary Kura Oncology's lead candidate, ziftomenib, shows dual-functionality in treating NPM1-mutant AML and overcoming resistance mutations. Company's financials robust with $477M in liquid assets, offsetting a manageable monthly cash burn of $10.2M, provid...

SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming Cantor Global Healthcare Conference...

2023-09-09 08:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...